Skip to main content

Clinical Trials Using Rituximab

Review the clinical trials studying rituximab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 124

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Status: Active
Location: 257 locations
Testing Continuous versus Intermittent Treatment with the Study Drug Zanubrutinib for Older Patients with Previously Untreated Mantle Cell Lymphoma
Status: Active
Location: 229 locations
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B Acute Lymphoblastic Leukemia
Status: Active
Location: 429 locations
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Status: Active
Location: 112 locations
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
Status: Active
Location: 49 locations
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients with Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
Status: Active
Location: 33 locations
BRAZAN Induction Therapy Followed by Zanubrutinib and Rituximab Maintenance Therapy with or without Sonrotoclax for the Treatment of Mantle Cell Lymphoma
Status: Active
Location: 18 locations
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Status: Active
Location: 16 locations
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Status: Active
Location: 11 locations
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Status: Active
Location: 10 locations
Pembrolizumab, Ibrutinib, and Rituximab for the Treatment of Relapse or Refractory Primary Central Nervous System Lymphoma
Status: Active
Location: 10 locations
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Status: Active
Location: 9 locations
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Status: Active
Location: 9 locations
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Status: Active
Location: 9 locations
Zanubrutinib in Combination with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone and High-Dose Methotrexate for the Treatment of Patients with Large B-cell Lymphoma with Central Nervous System Involvement
Status: Active
Location: 8 locations
Glucarpidase in Treating Patients with Central Nervous System B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: 8 locations
Enasidenib with or without Rituximab for the Treatment of Relapsed and Refractory IDH2-Mutant Angioimmunoblastic T-cell Lymphoma
Status: Active
Location: 7 locations
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma, PRoVen Trial
Status: Active
Location: 7 locations
Golcadomide and Rituximab as Bridging Therapy for Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma before CAR T-cell Therapy
Status: Active
Location: 7 locations
Vemurafenib and Obinutuzumab versus Standard Cladribine and Rituximab of the Treatment of Untreated Hairy Cell Leukemia
Status: Active
Location: 7 locations
Glofitamab-based Treatment in Older Adults with Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma or Transformed Lymphoma, GLORY Trial
Status: Active
Location: 7 locations
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: 7 locations
Rituximab and Epcoritamab for the Treatment of Follicular Lymphoma
Status: Active
Location: 6 locations
Loncastuximab Tesirine in Combination with Rituximab for the Treatment of Relapsed/Refractory Follicular Lymphoma
Status: Active
Location: 7 locations
Zanubrutinib, Bendamustine, and Rituximab for the Treatment of Previously Untreated Waldenstrom Macroglobulinemia, ZEBRA Trial
Status: Active
Location: 6 locations